- Synthesis of nevirapine and its major metabolite
-
Several synthetic methods were developed during the process optimization for the large scale synthesis of nevirapine (1), a non-nucleoside inhibitor of HIV-1 Reverse Transcriptase. The synthesis of its putative major metabolite 11-cyclopropyl-5,11-dihydro-4-hydroxymethyl-6H-[3,2-b:2',3'-e][1,4]dia zepin-6-one (2) and the oxidation of 2 to the corresponding aldehyde 3, are described.
- Grozinger,Fuchs,Hargrave,Mauldin,Vitous,Campbell,Adams
-
-
Read Online
- Preparation method for nevirapine intermediate
-
The invention provides a preparation method for a nevirapine intermediate. The preparation method comprises: performing a cyclization reaction of ammonia water, methyl cyanoacetate and methyl acetoacetate to form a compound hydroxyl: 2,6-dihydroxy-3-cyano-4-methylpyridine; adding triethylamine dropwise, introducing chlorine gas at the temperature until the reaction is complete, and obtaining 2,6-dichloro-3-cyano-4-methylpyridine; adding concentrated sulfuric acid, heating to 120 DEG C to react for 3-5 h, and then cooling to 60 DEG C; adding water to perform hydrolysis reaction, and obtaining 2,6-dichloro-3-amido-4-methylpyridine; adding a degradation reagent sodium hypochlorite, and obtaining a nevirapine intermediate 2,6-dichloro-3-amino-4- methylpyridine by Hofmann reaction. According tothe preparation method, commonly used phosphorus oxychloride is replaced with the directly introduced chlorine gas, which solves the problems that the wastewater content is too high, it is difficultto perform treatment and the odor of phosphorus oxychloride is bad, and the one-time yield of the product is 90.1%.
- -
-
Paragraph 0017; 0037; 0047; 0057; 0059; 0066-0067
(2019/01/14)
-
- COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE
-
The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
- -
-
Page/Page column 187
(2019/01/06)
-
- Method for preparing 3-amino-2-chloro-4-alkylpyridine or-4-arylpyridine
-
The present invention relates to a new process for preparing 3-amino-2-chloro-4-alkyl- or -4-aryl-pyridines on an industrial scale.
- -
-
-
- Method for the preparation of 5,11-dihydro-6h-dipyrido [3,2-b:2',3'-e][1,4]diazepines
-
This invention relates to a novel method for preparing certain dipyrido-diazepines.
- -
-
-
- Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. 4. 2-Substituted dipyridodiazepinones as potent inhibitors of both wild-type and cysteine-181 HIV-1 reverse transcriptase enzymes
-
The major cause of viral resistance to the potent human immunodeficiency virus type 1 reverse transcriptase (RT) inhibitor nevirapine is the mutation substituting cysteine for tyrosine-181 in RT (Y181C RT). An evaluation, against Y181C RT, of previously described analogs of nevirapine revealed that the 2-chlorodipyridodiazepinone 16 is an effective inhibitor of this mutant enzyme. The detailed examination of the structure-activity relationship of 2- substituted dipyridodiazepinones presented below shows that combined activity against the wild-type and Y181C enzymes is achieved with aryl substituents at the 2-position of the tricyclic ring system. In addition, the substitution pattern at C-4, N-5, and N-11 of the dipyridodiazepinone ring system optimum for inhibition of both wild-type and Y181C RT is no longer the 4-methyl-11- cyclopropyl substitution preferred against the wild-type enzyme but rather the 5-methyl-11-ethyl (or 11-cyclopropyl) pattern. The more potent 2- substituted dipyridodiazepinones were evaluated against mutant RT enzymes (L100I RT, K103N RT, P236L RT, and E138K RT) that confer resistance to other non-nucleoside RT inhibitors, and compounds 42, 62, and 67, with pyrrolyl, aminophenyl, and aminopyridyl substituents, respectively, at the 2-position, were found to be effective inhibitors of these mutant enzymes also.
- Proudfoot,Hargrave,Kapadia,Patel,Grozinger,McNeil,Cullen,Cardozo,Tong,Kelly,Rose,David,Mauldin,Fuchs,Vitous,Hoermann,Klunder,Raghavan,Skiles,et al.
-
p. 4830 - 4838
(2007/10/03)
-
- Method for preparing 3-amino-2-chloro-4-alkylpyridines
-
A process for the preparation of a 3-amino-2-chloro-4-alkylpyridine of the formula: STR1 wherein R is alkyl of from one to three carbon atoms, an intermediate in the preparation of certain 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine compounds useful in the prevention and treatment of HIV infection.
- -
-
-
